Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.45 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11083245 | 0.89 | MDM2 (0.52) | RAB9ATDP1HPGDMEN1KMT2A | |
| SCHEMBL27758940 | 0.78 | MMP12 (0.47) | RAB9AALDH1A1LMNAANPEPERAP2 | |
| SCHEMBL1303851 | 0.78 | NPC1 (0.60) | RAB9AGPR52CYP1A2ALDH1A1MEN1 | |
| SCHEMBL5870056 | 0.76 | CNR2 (0.49) | RAB9ACYP1A2HPGDMEN1KMT2A | |
| SCHEMBL6248066 | 0.76 | CNR2 (0.49) | RAB9ACYP1A2HPGDMEN1KMT2A | |
| SCHEMBL4061138 | 0.76 | CNR2 (0.49) | RAB9ACYP1A2HPGDMEN1KMT2A | |
| SCHEMBL11085580 | 0.75 | METAP2 (0.52) | RAB9AALDH1A1CYP2C19MEN1KMT2A | |
| SCHEMBL19104773 | 0.73 | SMN1; SMN2 (0.45) | GPR52CYP1A2CYP3A4PLOD2PLOD3 | |
| SCHEMBL8472563 | 0.73 | ERAP1 (0.49) | RAB9AHPGDMEN1KMT2ALMNA | |
| SCHEMBL7437317 | 0.72 | ALDH1A1 (0.50) | TDP1ALDH1A1KMT2ALMNAMMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-10407420-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2019-09-10 | — | — | US | disclosed |
| US-10392381-B2 | Prevention and treatment of non-alcoholic fatty liver disease | OHIO UNIVERSITY (US) | 2019-08-27 | — | — | US | disclosed |
| US-10023567-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023567-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170210737-A1 | IMIDAZOLE AND THIAZOLE COMPOSITIONS FOR MODIFYING BIOLOGICAL SIGNALING | OHIO UNIVERSITY (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210737-A1 | IMIDAZOLE AND THIAZOLE COMPOSITIONS FOR MODIFYING BIOLOGICAL SIGNALING | OHIO UNIVERSITY (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170202818-A1 | METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY | OHIO UNIVERSITY (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170202818-A1 | METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY | OHIO UNIVERSITY (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170196845-A1 | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | OHIO UNIVERSITY (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170196845-A1 | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | OHIO UNIVERSITY (US) | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392381-B2 | Prevention and treatment of non-alcoholic fatty liver disease | FABP1, LIPC, SLC10A1 | RAB9A 2970/4885GPR52 1829/4885TDP1 3862/4885 |
| US-10407420-B2 | Imidazole and thiazole compositions for modifying biological signaling | TYRO3, FGFR1, STAT6 | RAB9A 2968/4885GPR52 823/4885TDP1 4341/4885 |
| US-20170196845-A1 | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | FABP1, LIPC, SLC10A1 | RAB9A 2970/4885GPR52 1829/4885TDP1 3862/4885 |
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | TYRO3, FGFR1, STAT6 | RAB9A 2983/4885GPR52 832/4885TDP1 4338/4885 |
| US-20170210737-A1 | IMIDAZOLE AND THIAZOLE COMPOSITIONS FOR MODIFYING BIOLOGICAL SIGNALING | FGFR1, TYRO3, STAT6 | RAB9A 3095/4885GPR52 580/4885TDP1 4360/4885 |
| US-10023567-B2 | Imidazole and thiazole compositions for modifying biological signaling | FGFR1, TYRO3, STAT6 | RAB9A 3095/4885GPR52 580/4885TDP1 4360/4885 |
| US-20170202818-A1 | METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY | GSK3B, GSK3A, GSKIP | RAB9A 2018/4885GPR52 4469/4885TDP1 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.